FR2819724B1 - Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus - Google Patents

Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus

Info

Publication number
FR2819724B1
FR2819724B1 FR0100834A FR0100834A FR2819724B1 FR 2819724 B1 FR2819724 B1 FR 2819724B1 FR 0100834 A FR0100834 A FR 0100834A FR 0100834 A FR0100834 A FR 0100834A FR 2819724 B1 FR2819724 B1 FR 2819724B1
Authority
FR
France
Prior art keywords
polycharidic
inducing
immune response
bacterial antigens
protein structures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0100834A
Other languages
English (en)
Other versions
FR2819724A1 (fr
Inventor
Claude Agnes Reynaud
Jean Claude Weill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUT NECKER
Original Assignee
INSTITUT NECKER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0100834A priority Critical patent/FR2819724B1/fr
Application filed by INSTITUT NECKER filed Critical INSTITUT NECKER
Priority to EP02701320A priority patent/EP1372714A2/fr
Priority to PCT/FR2002/000240 priority patent/WO2002056909A2/fr
Priority to AU2002234667A priority patent/AU2002234667A1/en
Priority to JP2002557416A priority patent/JP2004529083A/ja
Priority to US10/466,950 priority patent/US20040043039A1/en
Publication of FR2819724A1 publication Critical patent/FR2819724A1/fr
Priority to AU2003236407A priority patent/AU2003236407A1/en
Application granted granted Critical
Publication of FR2819724B1 publication Critical patent/FR2819724B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR0100834A 2001-01-22 2001-01-22 Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus Expired - Fee Related FR2819724B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0100834A FR2819724B1 (fr) 2001-01-22 2001-01-22 Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus
PCT/FR2002/000240 WO2002056909A2 (fr) 2001-01-22 2002-01-22 Moyens pour induire une reponse immune aux antigenes bacteriens polysaccharidiques et aux structures proteiques des capsides de virus
AU2002234667A AU2002234667A1 (en) 2001-01-22 2002-01-22 Method for inducing an immune response to polysaccharide bacterial antigens and to protein structures of virus capsids
JP2002557416A JP2004529083A (ja) 2001-01-22 2002-01-22 多糖細菌抗原およびウイルスカプシドのタンパク質構造への免疫応答を誘導する手段
EP02701320A EP1372714A2 (fr) 2001-01-22 2002-01-22 Moyens pour induire une reponse immune aux antigenes bacteriens polysaccharidiques et aux structures proteiques des capsides de virus
US10/466,950 US20040043039A1 (en) 2001-01-22 2002-01-22 Method for inducing an immune response to polysaccharide bacterial antigens and to protein structures of virus capsides
AU2003236407A AU2003236407A1 (en) 2001-01-22 2003-08-21 Method of inducing an immune response to polysaccharide bacterial antigens and to protein structures of virus capsids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0100834A FR2819724B1 (fr) 2001-01-22 2001-01-22 Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus

Publications (2)

Publication Number Publication Date
FR2819724A1 FR2819724A1 (fr) 2002-07-26
FR2819724B1 true FR2819724B1 (fr) 2005-05-13

Family

ID=8859103

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0100834A Expired - Fee Related FR2819724B1 (fr) 2001-01-22 2001-01-22 Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus

Country Status (6)

Country Link
US (1) US20040043039A1 (fr)
EP (1) EP1372714A2 (fr)
JP (1) JP2004529083A (fr)
AU (2) AU2002234667A1 (fr)
FR (1) FR2819724B1 (fr)
WO (1) WO2002056909A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388049A1 (fr) 2002-05-30 2003-11-30 Immunotech S.A. Oligonucleotides immunostimulateurs et utilisations connexes
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU694299B2 (en) * 1994-10-13 1998-07-16 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
US6432679B1 (en) * 1998-06-12 2002-08-13 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220

Also Published As

Publication number Publication date
JP2004529083A (ja) 2004-09-24
US20040043039A1 (en) 2004-03-04
WO2002056909A3 (fr) 2003-10-30
AU2002234667A1 (en) 2002-07-30
FR2819724A1 (fr) 2002-07-26
AU2003236407A1 (en) 2003-09-25
WO2002056909A2 (fr) 2002-07-25
EP1372714A2 (fr) 2004-01-02

Similar Documents

Publication Publication Date Title
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
CY2016021I2 (el) Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
CY2016044I2 (el) Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg
SE0103754D0 (sv) Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density lipoprotein
PT759935E (pt) L1 de virus de papiloma recombinante
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
AU2002351239A8 (en) Antibody to latent membrane proteins and uses thereof
NO20023788L (no) Antistoff som binder humant interleukin-18 samt fremgangsmater ved fremstilling og anvendelse derav
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
DE69824013D1 (de) Impfstoff gegen hpv
MA54704A (fr) Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
EA201071366A1 (ru) Комбинированная вакцина против кори и вируса папилломы человека
EP1490099A4 (fr) Anticorps monoclonaux humains diriges contre la proteine m2 du virus de la grippe et methodes de production et d'utilisation de ceux-ci
FR2824326B1 (fr) Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
EP1412538A4 (fr) Procedes servant a detecter simultanement des antigenes de hcv et des anticorps anti-hcv
DE60232862D1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
AU2003228530A8 (en) Use of parapox b2l protein to modify immune responses to administered antigens
FR2819724B1 (fr) Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
WO2004071457A3 (fr) Vaccins et immunotherapies ameliores a base de proteine de choc thermique
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20081029